Table 4.

Disease and Patient Characteristics in Association With Bleeding During Dasatinib Therapy

Variable		Median (Range)	No.	No. Bleeding (%)	P
Age, y	Bleed	60 (18–78)			.33
	No bleed	55 (15–78)
WBC, × 10 g/L	Bleed	7.6 (0.7–144.4)			.15
	No bleed	13.7 (0.8–160.8)
Hemoglobin, g/dL	Bleed	10.2 (7.6–13.2)			.007
	No bleed	11.1 (6.3–16.6)
Platelet, × 10 g/L	Bleed	77 (3–681)			.001
	No bleed	255 (10–1615)
PB basophil %	Bleed	4 (0–44)			.29
	No bleed	2 (0–45)
PB blast %	Bleed	6 (0–63)			.049
	No bleed	0 (0–99)
BM blast %	Bleed	13 (0–88)			.002
	No bleed	3 (0–98)
BM basophil %	Bleed	3 (0–41)			.21
	No bleed	2 (0–57)
CML duration, mo	Bleed	77 (1–216)			.049
	No bleed	60 (1–207)
Sex	Female		76	20 (26)	.34
	Male		62	12 (19)
Pulmonary history	Yes		16	2 (13)	.28
	No		122	30 (25)
Diabetes history	Yes		10	2 (20)	.80
	No		128	30 (23)
Cardiac history	Yes		18	5 (28)	.62
	No		120	27 (22)
Renal history	Yes		12	1 (8)	.20
	No		126	31 (25)
Gastrointestinal history*	Yes		25	7 (25)	.53
	No		113	25 (22)
HTN	Yes		37	8 (22)	.79
	No		101	24 (24)
Prior SCT	Yes		11	3 (27)	.74
	No		127	29 (23)
Prior IFN-α	Yes		81	23 (28)	.08
	No		57	9 (16)
CML phases					.007
CP			63	7 (11)
AP			38	13 (34)
BP			35	12 (34)	.002 (CP vs AP/BP)
Dose schedule					.17
QD			39	6 (15)
BID			99	26 (26)
Dose, mg/day					.45
<100			15	2 (13)
100			21	3 (14)
105–140			93	24 (26)
>140			9	3 (33)

WBC indicates white blood cell; PB, peripheral blood; BM, bone marrow; CML, chronic myelogenous leukemia; HTN, hypertension; SCT: stem cell transplantation; IFN-α, interferon-α; CP, chronic phase; AP, accelerated phase; BP, blast phase; QD, daily; BID, twice daily.

^*Gastrointestinal history included gastroesophageal reflux disease, hiatal hernial, esophagitis, peptic ulcer disease, gastritis, Mallory-Weiss syndrome, duodenitis, and diverticulitis.